Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-09-07

Clinical Trial Update: Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia [Phase 4]

View source ↗

Summary

A Phase 4 discontinuation study evaluated the durability of milnacipran's effects in fibromyalgia, with results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SAVELLA (milnacipran hydrochloride)

Snippet

Sponsor: Forest Laboratories | Conditions: Fibromyalgia | Phase 4 | Status: COMPLETED | Results posted: 2011-09-07